Meta-analysis of the efficacy and safety of sintilimab for treating advanced non-small cell lung cancer

Lung cancer is the leading cause of death from malignant tumors in China, and non-small cell lung cancer (NSCLC) accounts for >80% of all types of lung cancer. Novel immunotherapeutic agents targeting programmed death protein-1 (PD-1) and its ligands [programmed death ligands (PD-L)1 and 2] have...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Jiejie, Wu, Xueyan, Wu, Jianmei, Huang, Fang, Xu, Luning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580245/
https://www.ncbi.nlm.nih.gov/pubmed/36284649
http://dx.doi.org/10.3892/ol.2022.13545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580245/
https://www.ncbi.nlm.nih.gov/pubmed/36284649
http://dx.doi.org/10.3892/ol.2022.13545

Ejemplares similares